The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Open accessThe DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
Liraglutide is a glucagon-like peptide-1 (GLP-1) analog marketed for the treatment of type 2 diabetes. Besides lowering blood glucose, liraglutide also reduces body weight. It is not fully understood how liraglutide induces weight loss or to what degree liraglutide acts directly in the brain. Here, we determined that liraglutide does not activate GLP-1-producing neurons in the hindbrain, and liraglutide-dependent body weight reduction in rats was independent of GLP-1 receptors (GLP-1Rs) in the vagus nerve, area postrema, and paraventricular nucleus. Peripheral injection of fluorescently labeled liraglutide in mice revealed the presence of the drug in the circumventricular organs. Moreover, labeled liraglutide bound neurons within the arcuate nucleus (ARC) and other discrete sites in the hypothalamus. GLP-1R was necessary for liraglutide uptake in the brain, as liraglutide binding was not seen in Glp1r(-/-) mice. In the ARC, liraglutide was internalized in neurons expressing proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART). Electrophysiological measurements of murine brain slices revealed that GLP-1 directly stimulates POMC/CART neurons and indirectly inhibits neurotransmission in neurons expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) via GABA-dependent signaling. Collectively, our findings indicate that the GLP-1R on POMC/CART-expressing ARC neurons likely mediates liraglutide-induced weight loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1R and GIP-R have been identified in brain regions involved in the regulation of appetite, satiety, food/energy intake and energy expenditure, which is consistent with the significant impact on body weight observed with incretin therapy.”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These studies have demonstrated that the principal sites of action accessible to these drugs are GLP-1R neurons in circumventricular organs, particularly the AP and ME, and those in immediately adjacent regions—the NTS and arcuate nucleus of the hypothalamus (16, 51, 63‐66).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The individual necessity of distinct GLP-1R neuron populations for the anorectic and weight loss effects of GLP-1RAs has now been claimed by multiple studies using various loss-of-function approaches in rodents (47, 50‐54, 69).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Preclinical studies also indicate that tanycytes, specialized glial cells within the CNS, may facilitate the transportation of peripheral GLP-1RAs, such as semaglutide, into the CNS, bypassing the blood-brain barrier to access appetite-regulating hypothalamic regions such as the arcuate nucleus (60, 61).”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [61]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent mechanistic studies, primarily conducted in rodents, have identified a number of sites of direct action putatively mediating the effects of GLP-1-based AOMs on eating and body weight, including the area postrema and nucleus tractus solitarius (47‐49), locus coeruleus (50), hypothalamic arcuate (51, 52) and dorsomedial nuclei (53), and the lateral septal nucleus (54).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [51]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central nervous system control of food intake
Schwartz, M. W., Woods, S. C., Porte, D., Seeley, R. J., & Baskin, D. G. (2000) · Nature · doi:10.1038/35007534 · Cited by 6,451 · cited 9×
“In 7 of 7 cells (from 5 mice), GLP-1(7-36)amide failed to change the current in the presence of bicuculline (Figure 2, D and F), demonstrating that GABA-A receptor activation was likely responsible for the inhibitory effects of GLP-1(7-36)amide on NPY neurons.”
InfluentialDrucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 2×
“Physiologically, GLP-1 released from endocrine cells lining the gut acts peripherally (13, 42).”
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 4×
“Given the well-known role of NTS-produced GLP-1 in appetite regulation, it is tempting to speculate that peripheral administration of GLP-1 or analogs activates NTS GLP-1–positive neurons that in turn reduce appetite (22, 23).”
InfluentialObesity is associated with hypothalamic injury in rodents and humans.
Thaler, J. P., Yi, C.-X., Schur, E. A., Guyenet, S. J., Hwang, B. H., Dietrich, M. O., Zhao, X., Sarruf, D. A., Izgur, V., Maravilla, K. R., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59660 · Cited by 1,857
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“…analogs, like exenatide and lixisenatide, display a marked reduction of GE, which may contribute to short-term effects on food intake, while liraglutide and exenatide, formulated for slow release, have only a minor effect on GE, which then cannot be the mediator of the body weight effects (16, 17).”
Hypothalamic CART is a new anorectic peptide regulated by leptin
Kristensen, P., Judge, M. E., Thim, L., Ribel, U., Christjansen, K. N., Wulff, B. S., Clausen, J. T., Jensen, P. B., Madsen, O. D., Vrang, N., et al. (1998) · Nature · doi:10.1038/29993 · Cited by 1,282 · cited 1×
“…access to the brain and how they may affect the key neuronal pathways that regulate energy balance, such as the neuropeptide Y/agouti-related peptide (NPY/ AgRP) and proopiomelanocortin/cocaine-and amphetamine-regulated transcript (POMC/CART) neurons located in the arcuate nucleus (ARC) (7–11).”
Self-citationAstrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163 · cited 1×
“Liraglutide dose dependently lowers body weight by reducing energy intake via an overall appetite reduction (31, 32).”
NPY/AgRP Neurons Are Essential for Feeding in Adult Mice but Can Be Ablated in Neonates
Luquet, S., Perez, F. A., Hnasko, T. S., & Palmiter, R. D. (2005) · Science · doi:10.1126/science.1115524 · Cited by 1,125
Research works printed but not linked: 1
- Astrup A, Rossner S, Van Gaal L. Effects of lirag- lutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(9701):1606-1616. · DOI · Paper page
Cited by
Items 101–200 of 958
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125
“Exogenously administered GLP-1 or GLP-1RAs, however, may reach the CNS via circumventricular organs 109,235 .”
InfluentialTanycytes control hypothalamic liraglutide uptake and its anti-obesity actions
Imbernon, M., Saponaro, C., Helms, H. C. C., Duquenne, M., Fernandois, D., Deligia, E., Denis, R. G. P., Chao, D. H. M., Rasika, S., Staels, B., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.06.002 · Cited by 124
Appetite Regulation: Hormones, Peptides, and Neurotransmitters and Their Role in Obesity
Miller, G. D. (2019) · American Journal of Lifestyle Medicine · doi:10.1177/1559827617716376 · Cited by 124
Hindbrain circuits in the control of eating behaviour and energy balance
Cheng, W., Gordian, D., Ludwig, M. Q., Pers, T. H., Seeley, R. J., & Myers, M. G. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00606-9 · Cited by 134
Activation of murine pre-proglucagon–producing neurons reduces food intake and body weight
Gaykema, R. P., Newmyer, B. A., Ottolini, M., Raje, V., Warthen, D. M., Lambeth, P. S., Niccum, M., Yao, T., Huang, Y., Schulman, I. G., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci81335 · Cited by 123
Cheng, W., Gonzalez, I., Pan, W., Tsang, A. H., Adams, J., Ndoka, E., Gordian, D., Khoury, B., Roelofs, K., Evers, S. S., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.12.012 · Cited by 123
GLP-1 and Amylin in the Treatment of Obesity
Jorsal, T., Rungby, J., Knop, F. K., & Vilsbøll, T. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0693-3 · Cited by 125
Marzook, A., Tomas, A., & Jones, B. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.678055 · Cited by 121
Targher, G., Mantovani, A., & Byrne, C. D. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00338-7 · Cited by 121
Neural effects of gut‐ and brain‐derived glucagon‐like peptide‐1 and its receptor agonist
Katsurada, K., & Yada, T. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12464 · Cited by 119
“These effects were diminished with simultaneous central infusion of the GLP1 receptor antagonist exendin(9-39), and abolished in GLP-1 receptor knockout mice.”
BackgroundAldawsari, M., Almadani, F. A., Almuhammadi, N., Algabsani, S., Alamro, Y., & Aldhwayan, M. (2023) · Diabetes, Metabolic Syndrome and Obesity · doi:10.2147/dmso.s387116 · Cited by 115
“As demonstrated by recent animal studies, the GLP-1 receptor can be mediated through multiple sites in the brain, including the brainstem and hypothalamic nuclei that regulate homeostatic feeding appetite.(37,38) A randomized, crossover, placebo-controlled trial by van Bloemendaal et al 2014 included 48 patients with…”
BackgroundCentral administration of GLP-1 and GIP decreases feeding in mice
NamKoong, C., Kim, M. S., Jang, B.-T., Lee, Y. H., Cho, Y.-M., & Choi, H. J. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.06.031 · Cited by 114
GLP-1 based therapeutics: simultaneously combating T2DM and obesity
Heppner, K. M., & Perez-Tilve, D. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00092 · Cited by 115
ten Kulve, J. S., Veltman, D. J., van Bloemendaal, L., Barkhof, F., Deacon, C. F., Holst, J. J., Konrad, R. J., Sloan, J. H., Drent, M. L., Diamant, M., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3754-x · Cited by 109
G protein-coupled receptors as targets for anti-diabetic therapeutics
Oh, D. Y., & Olefsky, J. M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.4 · Cited by 117
Mahapatra, M. K., Karuppasamy, M., & Sahoo, B. M. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03302-1 · Cited by 110
“It also activates gastro-mechano receptors which in turn suppresses the satiation centre situated in brainstem by relaying signals through vagus nerve (35, 36).”
BackgroundG Protein–Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus
Riddy, D. M., Delerive, P., Summers, R. J., Sexton, P. M., & Langmead, C. J. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014373 · Cited by 108
“…effects of b3- adrenoceptor agonists on lipolysis and heat production in brown fat, it was apparent even in early studies thatb3-adrenoceptor (or atypicalb-adrenoceptor) agonists improve glucose tolerance and insulin sensitivity (Cawthorne et al., 1984; Sennitt et al., 1985;Williams et al., 1999).”
Ong, Z. Y., Liu, J.-J., Pang, Z. P., & Grill, H. J. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.150 · Cited by 112
“…is of clinical relevance given that brain fMRI responses to food cues predict future body weight gain (Sun et al, 2015) and that exposure to palatable foods and food cues increases the likelihood of reinstatement or relapse to unhealthy eating Neuropsychopharmacology habits (Stanton et al, 1990).”
Glucagon-like peptide-1 suppresses neuroinflammation and improves neural structure
Yoon, G., Kim, Y.-K., & Song, J. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.104615 · Cited by 107
The GLP-1 journey: from discovery science to therapeutic impact
Drucker, D. J. (2024) · Journal of Clinical Investigation · doi:10.1172/jci175634 · Cited by 126
“Injection of fluorescent liraglutide labelled neurons in circum-ventricular organs, as well as the arcuate nucleus, showed brain uptake of labelled liraglutide was abolished in Glp1r –/– mice, showing that brain uptake of liraglutide is dependent on the canonical GLP-1R (11).”
Varin, E. M., Mulvihill, E. E., Baggio, L. L., Koehler, J. A., Cao, X., Seeley, R. J., & Drucker, D. J. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.055 · Cited by 104
“The CNS actions of small peptide GLP-1R agonists have been associated with direct access to hypothalamic and hindbrain GLP-1R neurons (Knudsen and Lau, 2019; Secher et al., 2014).”
BackgroundMarty, V. N., Farokhnia, M., Munier, J. J., Mulpuri, Y., Leggio, L., & Spigelman, I. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.599646 · Cited by 102
Alhadeff, A. L., Mergler, B. D., Zimmer, D. J., Turner, C. A., Reiner, D. J., Schmidt, H. D., Grill, H. J., & Hayes, M. R. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.246 · Cited by 102
“…periphery and central nervous system (CNS) are involved in mediating the metabolic effects of these exogenous GLP-1R agonists (Kanoski et al, 2011; Secher et al, 2014; Sisley et al, 2014) and thus it is important to understand the contributions of discrete GLP-1R populations to energy balance…”
Backgroundten Kulve, J. S., Veltman, D. J., van Bloemendaal, L., Barkhof, F., Drent, M. L., Diamant, M., & IJzerman, R. G. (2016) · Diabetes Care · doi:10.2337/dc15-0772 · Cited by 102
“GLP-1 receptors in the CNS are required for the anorectic and weight-reducing effects of liraglutide (29).”
BackgroundPrinz, P., & Stengel, A. (2017) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm16194 · Cited by 118
“CART-containing neurons and to inhibit NPY/AgRP-containing neurons in the ARC resulting in a decrease of body weight.(94) However, it is of note that after reaching the circulation endogenous GLP-1 is rapidly degraded by the enzyme dipeptidyl peptidase IV.”
BackgroundA Role for GLP-1 in Treating Hyperphagia and Obesity
Grill, H. J. (2020) · Endocrinology · doi:10.1210/endocr/bqaa093 · Cited by 101
Liraglutide for Type 2 diabetes and obesity: a 2015 update
Iepsen, E. W., Torekov, S. S., & Holst, J. J. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1054810 · Cited by 101
“However, direct injection of exendin-9 into the ARC, but not into PVN, abolished the effect of liraglutide on food intake and body weight, suggesting that the ARC and not the PVN is involved [22].”
BackgroundInfluentialGLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway
Xiang, J., Qin, L., Zhong, J., Xia, N., & Liang, Y. (2023) · Diabetes, Metabolic Syndrome and Obesity · doi:10.2147/dmso.s425642 · Cited by 100
PPG neurons of the lower brain stem and their role in brain GLP-1 receptor activation
Trapp, S., & Cork, S. C. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00333.2015 · Cited by 100
A survey of the mouse hindbrain in the fed and fasted states using single-nucleus RNA sequencing
Dowsett, G. K. C., Lam, B. Y. H., Tadross, J. A., Cimino, I., Rimmington, D., Coll, A. P., Polex-Wolf, J., Knudsen, L. B., Pyke, C., & Yeo, G. S. H. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101240 · Cited by 98
Self-citationSingh, I., Wang, L., Xia, B., Liu, J., Tahiri, A., El Ouaamari, A., Wheeler, M. B., & Pang, Z. P. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00914-3 · Cited by 98
“It also has been shown that the GLP-1R agonist, semaglutide/liraglutide, directly activates POMC neurons and indirectly inhibits NPY/AGRP neurons in the ARC [33, 34].”
BackgroundResultInfluentialHansen, H. H., Barkholt, P., Fabricius, K., Jelsing, J., Terwel, D., Pyke, C., Knudsen, L. B., & Vrang, N. (2015) · Brain Research · doi:10.1016/j.brainres.2015.12.052 · Cited by 103
Self-citationBurcelin, R., & Gourdy, P. (2017) · Obesity Reviews · doi:10.1111/obr.12465 · Cited by 94
“Murine studies have indicated that liraglutide acts on neuronal pathways in the hypothalamus such as the proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART) pathway and the neuropeptide Y/agouti-related peptide (NPY/AgRP) pathway, which are involved in the regulation of appetite and ene…”
BackgroundSalvatore, T., Galiero, R., Caturano, A., Vetrano, E., Loffredo, G., Rinaldi, L., Catalini, C., Gjeloshi, K., Albanese, G., Di Martino, A., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10092274 · Cited by 98
Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency
Alavi, S. E., Cabot, P. J., & Moyle, P. M. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00308 · Cited by 95
Cheng, W., Ndoka, E., Hutch, C., Roelofs, K., MacKinnon, A., Khoury, B., Magrisso, J., Kim, K. S., Rhodes, C. J., Olson, D. P., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.134359 · Cited by 97
A comprehensive spatio-cellular map of the human hypothalamus
Tadross, J. A., Steuernagel, L., Dowsett, G. K. C., Kentistou, K. A., Lundh, S., Porniece, M., Klemm, P., Rainbow, K., Hvid, H., Kania, K., et al. (2025) · Nature · doi:10.1038/s41586-024-08504-8 · Cited by 112
“Neverthe-less, studies supporting the more detailed molecular modes of action are derived from studies in mice 8–10 .”
InfluentialSelf-citationSalinas, C. B. G., Lu, T. T.-H., Gabery, S., Marstal, K., Alanentalo, T., Mercer, A. J., Cornea, A., Conradsen, K., Hecksher-Sørensen, J., Dahl, A. B., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-28496-6 · Cited by 95
Self-citationLoss of dorsomedial hypothalamic GLP-1 signaling reduces BAT thermogenesis and increases adiposity
Lee, S. J., Sanchez-Watts, G., Krieger, J.-P., Pignalosa, A., Norell, P. N., Cortella, A., Pettersen, K. G., Vrdoljak, D., Hayes, M. R., Kanoski, S. E., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.03.008 · Cited by 95
“(C) Relative mRNA expression in the ARC. ns: NPY, CART, POMC, and AgRP.”
BackgroundInfluentialVosoughi, K., Atieh, J., Khanna, L., Khoshbin, K., Prokop, L. J., Davitkov, P., Murad, M. H., & Camilleri, M. (2021) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.101213 · Cited by 97
“[6,7] GLP-1 and GLP-1 agonists or analogs also reduce appetite through effects on several regions of the human central nervous system that express GLP-1 receptors including the parietal and orbitofrontal cortex, hypothalamus, [8] and medulla (such as the nucleus of solitary tract); for example, the GLP-1 analog, lirag…”
BackgroundControl of insulin secretion by GLP-1
Jones, B. J., Bloom, S. R., Buenaventura, T., Tomás, A., & Rutter, G. A. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.013 · Cited by 107
“1R transcytosis, already demonstrated for leptin [162] and hinted at for the GLP-1R [67].”
Krieger, J.-P. (2020) · Peptides · doi:10.1016/j.peptides.2020.170342 · Cited by 91
Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys
Thomsen, M., Holst, J. J., Molander, A., Linnet, K., Ptito, M., & Fink-Jensen, A. (2019) · Psychopharmacology · doi:10.1007/s00213-018-5089-z · Cited by 93
The regulation of PKA signaling in obesity and in the maintenance of metabolic health
London, E., & Stratakis, C. A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108113 · Cited by 102
Magruder, M. L., Miskiewicz, M. J., Rodriguez, A. N., & Mont, M. A. (2024) · The Journal of Arthroplasty · doi:10.1016/j.arth.2023.12.023 · Cited by 92
Dong, Y., Carty, J., Goldstein, N., He, Z., Hwang, E., Chau, D., Wallace, B., Kabahizi, A., Lieu, L., Peng, Y., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101352 · Cited by 93
“Changes in cellular activity in response to GLP-1 and GLP-1R agonists were reported in response to acute administration in an ex-vivo preparation [14,15,17].”
BackgroundResultInfluentialGlucose-dependent insulinotropic polypeptide (GIP)
Müller, T. D., Adriaenssens, A. E., Ahrén, B., Blüher, M., Birkenfeld, A. L., Campbell, J. E., Coghlan, M. P., D’Alessio, D. D., Deacon, C. F., DelPrato, S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102118 · Cited by 113
Reappraising the role of the vagus nerve in GLP-1-mediated regulation of eating
Brierley, D. I., & de Lartigue, G. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15603 · Cited by 92
“…Glp1rexpressing vagal sensory neurons and PPG neurons in the NTS forms the basis of a prevalent, but largely untested, hypothesis - that peripheral GLP-1 acts as a satiation/satiety signal by vagal-dependent activation of the central GLP-1 system (Grill, 2020; Krieger, 2020; Secher et al., 2014).”
BackgroundObesity and the kidney: mechanistic links and therapeutic advances
Yau, K., Kuah, R., Cherney, D. Z. I., & Lam, T. K. T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00951-7 · Cited by 91
“Additional results indicate that the GLP1RA liraglutide is internalized upon binding to the GLP1R and alters hypo-thalamic neurons to affect energy balance 100 , while GLPR signalling in the nucleus of the solitary tract is necessary for liraglutide to reduce feeding and weight 101 .”
Newer GLP-1 receptor agonists and obesity-diabetes
Brown, E. E., Cuthbertson, D. J., & Wilding, J. P. H. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.009 · Cited by 110
Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1
Paternoster, S., & Falasca, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00584 · Cited by 91
“This signaling has proven to be essential for the Liraglutide mediated weight loss in rats (163).”
BackgroundQue, Q., Guo, X., Zhan, L., Chen, S., Zhang, Z., Ni, X., Ye, B., & Wan, S. (2019) · Journal of Inflammation · doi:10.1186/s12950-019-0218-y · Cited by 90
Dong, M., Wen, S., & Zhou, L. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s375559 · Cited by 90
“Some of the GLP-1RAs have been proven to cross through the BBB via passive diffusion.34,46,48,68 In addition, GLP-1RAs could cross the BBB via the GLP-1 receptor-mediated uptake mechanism.52 Liraglutide has access to specific areas of the brain associated with appetite regulation and was measured in selected CVOs and…”
MethodResultRoth, C. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4091774 · Cited by 89
“GLP-1 binds to receptors (GLP-1Rs) in the vagus as well as to appetite-related sites in the hindbrain (nucleus of the solitary tract, area postrema) and the hypothalamus (arcuate and dorsomedial nuclei) [152–156], which are areas that are not fully blocked from the peripheral circulation by the blood-brain barrier [15…”
BackgroundQuarta, C., Clemmensen, C., Zhu, Z., Yang, B. S., Joseph, S. S., Lutter, D., Yi, C., Graf, E., García‐Cáceres, C., Legutko, B., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.023 · Cited by 93
“While GLP-1Rs located in the CNS mediate the effects of GLP-1 agonists on BW control (Secher et al., 2014), peripheral mechanisms contribute to the favorable actions on glucose metabolism (Sisley et al.”
BackgroundA systematic review on different models of inducing obesity in animals: Advantages and limitations
Suleiman, J. B., Mohamed, M., & Bakar, A. B. A. (2020) · Journal of Advanced Veterinary and Animal Research · doi:10.5455/javar.2020.g399 · Cited by 112
“Obesity develops in these rats as they become hyperphagia and have hyperinsulinemia and insulin resistance [102].”
BackgroundGLP-1-directed NMDA receptor antagonism for obesity treatment
Petersen, J., Ludwig, M. Q., Juozaityte, V., Ranea-Robles, P., Svendsen, C., Hwang, E., Kristensen, A. W., Fadahunsi, N., Lund, J., Breum, A. W., et al. (2024) · Nature · doi:10.1038/s41586-024-07419-8 · Cited by 89
“…GLP-1 analogues engage central appetite circuits through distinct subpopulations of neurons (most notably in the brainstem and the hypothalamus) 36 , feedforward neural pathways modulated by inhibition of NMDA receptors specifically in GLP-1-receptor-positive neurons may differ from those…”
Steinberg, W. M., Buse, J. B., Ghorbani, M. L. M., Ørsted, D. D., Nauck, M. A., the LEADER Steering Committee, & on behalf of the LEADER Trial Investigators (2017) · Diabetes Care · doi:10.2337/dc16-2747 · Cited by 87
“(24,25) leading to altered expression of pancreatic enzymes specifically favoring”
BackgroundRoth, C. L., Perez, F. A., Whitlock, K. B., Elfers, C., Yanovski, J. A., Shoemaker, A. H., & Abuzzahab, M. J. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14224 · Cited by 87
“GLP-1 binds to receptors in the vagus nerve as well as to appetite-related sites in the hindbrain (nucleus of the solitary tract, area postrema) and the hypothalamus (arcuate and dorsomedial nuclei).(31) GLP-1 functions as a satiety hormone, promoting reduced food intake and more rapid meal termination,(32) as well as…”
BackgroundGlucocorticoids, stress and eating: The mediating role of appetite‐regulating hormones
Kuckuck, S., van der Valk, E. S., Scheurink, A. J. W., van der Voorn, B., Iyer, A. M., Visser, J. A., Delhanty, P. J. D., van den Berg, S. A. A., & van Rossum, E. F. C. (2022) · Obesity Reviews · doi:10.1111/obr.13539 · Cited by 106
“mediated by the central, rather than peripheral, endogenous GLP-1 system.(98,147) In addition, targeting GLP-1 and its receptor GLP-1R is seen as a promising approach for the development of novel antide-”
BackgroundVogel, H., Wolf, S., Rabasa, C., Rodriguez-Pacheco, F., Babaei, C. S., Stöber, F., Goldschmidt, J., DiMarchi, R. D., Finan, B., Tschöp, M. H., et al. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.07.039 · Cited by 86
“, 2014)(Secher et al., 2014), or an important mediator of blood glucose changes induced by GLP-1 by other studies (Sandoval et al.”
BackgroundLeveraging the Gut to Treat Metabolic Disease
Gimeno, R. E., Briere, D. A., & Seeley, R. J. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.02.014 · Cited by 83
Enteroendocrine cell regulation of the gut-brain axis
Barton, J. R., Londregan, A., Alexander, T. D., Entezari, A. A., Covarrubias, M., & Waldman, S. A. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1272955 · Cited by 102
Glucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress
Diz-Chaves, Y., Herrera-Pérez, S., González-Matías, L. C., Lamas, J. A., & Mallo, F. (2020) · Nutrients · doi:10.3390/nu12113304 · Cited by 84
“administration of GLP-1 or its analogs induces satiation [195,237].”
BackgroundMethodInfluentialGorgojo‐Martínez, J. J., Basagoiti‐Carreño, B., Sanz‐Velasco, A., Serrano‐Moreno, C., & Almodóvar‐Ruiz, F. (2019) · International Journal of Clinical Practice · doi:10.1111/ijcp.13399 · Cited by 82
Satiety: a gut–brain–relationship
Barakat, G. M., Ramadan, W., Assi, G., & Khoury, N. B. E. (2024) · The Journal of Physiological Sciences · doi:10.1186/s12576-024-00904-9 · Cited by 82
“GLP-1 receptors are abundant in the arcuate nucleus as well as the hypothalamus which contains projections to the hunger centers [18, 19].”
BackgroundThe Role of the Gut Microbiota in the Gut–Brain Axis in Obesity: Mechanisms and Future Implications
van Son, J., Koekkoek, L. L., la Fleur, S. E., Serlie, M. J. M., & Nieuwdorp, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062993 · Cited by 91
“In rodents, GLP-1RAs exert this effect by activating POMC/CART neurons and indirectly inhibiting NPY/AgRP through GABAergic transmission [117].”
BackgroundGLP-1 and Its Analogs: Does Sex Matter?
Börchers, S., & Skibicka, K. P. (2025) · Endocrinology · doi:10.1210/endocr/bqae165 · Cited by 77
Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity
Anandhakrishnan, A., & Korbonits, M. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i20.572 · Cited by 82
Lingvay, I., Desouza, C. V., Lalic, K. S., Rose, L., Hansen, T., Zacho, J., & Pieber, T. R. (2018) · Diabetes Care · doi:10.2337/dc17-2381 · Cited by 81
Jiang, W., Li, W., Cheng, J., Li, W., & Cheng, F. (2022) · Sleep And Breathing · doi:10.1007/s11325-022-02768-y · Cited by 98
“It can directly stimulate POMC neurons while inhibiting arcuate nucleus neuropeptide y (NPY) and AgRP neurons, reducing hunger and increasing satiety [13].”
BackgroundDe Giorgi, R., Ghenciulescu, A., Dziwisz, O., Taquet, M., Adler, A. I., Koychev, I., Upthegrove, R., Solmi, M., McCutcheon, R., Pillinger, T., et al. (2025) · Nature Mental Health · doi:10.1038/s44220-025-00390-x · Cited by 77
“249), liraglutide 250 and semaglutide 5 did not cross the blood–brain barrier but instead interacted with the brain through the circumventricular organs.”
Lee, S., & Lee, D. Y. (2017) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2017.22.1.15 · Cited by 79
Farkas, I., Vastagh, C., Farkas, E., Bálint, F., Skrapits, K., Hrabovszky, E., Fekete, C., & Liposits, Z. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00214 · Cited by 79
McKinley, M. J., Denton, D. A., Ryan, P. J., Yao, S. T., Stefanidis, A., & Oldfield, B. J. (2019) · Journal of Neuroendocrinology · doi:10.1111/jne.12689 · Cited by 78
An, J., Zhou, Y., Zhang, M., Xie, Y., Ke, S., Liu, L., Pan, X., & Chen, Z. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.111932 · Cited by 78
Obesity in Adults: A 2022 Adapted Clinical Practice Guideline for Ireland
Breen, C., O’Connell, J., Geoghegan, J., O'Shea, D. B., Birney, S., Tully, L., Gaynor, K., O’Kelly, M., O’Malley, G., O’Donovan, C. B., et al. (2022) · Obesity Facts · doi:10.1159/000527131 · Cited by 95
Adriaenssens, A., Broichhagen, J., de Bray, A., Ast, J., Hasib, A., Jones, B., Tomas, A., Burgos, N. F., Woodward, O., Lewis, J., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.164921 · Cited by 77
“However, previous studies using fluorescently labeled GLP-1, liraglutide, and semaglutide demonstrated that GLP-1 and GLP1RAs largely did not permeate the BBB and, instead, worked through select Glp1r-expressing regions in close proximity to the cerebral ventricles (40, 51, 52).”
Exenatide induces frataxin expression and improves mitochondrial function in Friedreich ataxia
Igoillo‐Esteve, M., Oliveira, A. F., Cosentino, C., Fantuzzi, F., Demarez, C., Toivonen, S., Hu, A., Chintawar, S., Lopes, M., Pachera, N., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.134221 · Cited by 84
“Several reports describe that exenatide and GLP-1 analogs with higher molecular weight (through linkage with fatty acids and/or carrier proteins) can directly access the brain, especially the hypothalamus (70, 71).”
BackgroundPerens, J., Salinas, C. G., Skytte, J. L., Roostalu, U., Dahl, A. B., Dyrby, T. B., Wichern, F., Barkholt, P., Vrang, N., Jelsing, J., et al. (2020) · Neuroinformatics · doi:10.1007/s12021-020-09490-8 · Cited by 92
“…clearing techniques have, together with ex vivo imaging technologies such as light sheet fluorescence microscopy (LSFM), enabled whole-organ imaging (Chung et al. 2013; Ertürk et al. 2012; Jensen et al. 2015; Kjaergaard et al. 2019; Renier et al. 2014; Rocha et al. 2019; Secher et al. 2014).”
BackgroundMethodSelf-citationThe Regulation of Peripheral Metabolism by Gut-Derived Hormones
Sun, E. W. L., Martin, A. M., Young, R. L., & Keating, D. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00754 · Cited by 71
“Indeed, Liraglutide can directly activate anorectic POMC/CART neurons in rodents and thus, indirectly inhibit orexigenic AgRP/NPY neurons in the arcuate nucleus (ARC) to reduce food intake (101).”
BackgroundThe incretin/glucagon system as a target for pharmacotherapy of obesity
Del Prato, S., Gallwitz, B., Holst, J. J., & Meier, J. J. (2022) · Obesity Reviews · doi:10.1111/obr.13372 · Cited by 77
“activation of satiety pathways and efferent pathways regulating GI function (Figure 2).(66,67,95,100,101) GLP-1 also reduces glucagon secretion by alpha cells, thereby inhibiting hepatic glucose production.”
BackgroundDecara, J., Rivera, P., Arrabal, S., Vargas, A., Serrano, A., Pavón, F. J., Dieguez, C., Nogueiras, R., Rodríguez de Fonseca, F., & Suárez, J. (2018) · Acta Physiologica · doi:10.1111/apha.13008 · Cited by 76
“In this regard, liraglutide could prevent AgRP/NPY-induced orexigenic stimuli, as well as directly activating neurons expressing POMC and CART, key hypothalamic peptides for feelings of satiety.(45,46) The primary weight loss mechanism of liraglutide and other long-acting GLP-1R agonists is not related to their little…”
BackgroundLiraglutide for Weight Management in Children and Adolescents With Prader–Willi Syndrome and Obesity
Diene, G., Angulo, M., Hale, P. M., Jepsen, C. H., Hofman, P. L., Hokken‐Koelega, A. C. S., Ramesh, C. K., Turan, S., & Tauber, M. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac549 · Cited by 86
Actions of glucagon‐like peptide‐1 receptor ligands in the gut
Holst, J. J., Andersen, D. B., & Grunddal, K. V. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15611 · Cited by 73
Volpe, M., & Gallo, G. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1136340 · Cited by 103
“Beside the glucoselowering effect related to the stimulation of insulin secretion, liraglutide slows gastric emptying and increases hypothalamic sense of satiety, stimulating pro-opiomelanocortin (POMC) neurons (64).”
BackgroundVallöf, D., Kalafateli, A. L., & Jerlhag, E. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-00923-1 · Cited by 72
Farkas, E., Szilvásy-Szabó, A., Ruska, Y., Sinkó, R., Rasch, M. G., Egebjerg, T., Pyke, C., Gereben, B., Knudsen, L. B., & Fekete, C. (2021) · Brain Structure and Function · doi:10.1007/s00429-020-02189-1 · Cited by 73
“Due to the very short half-life, the ability of endogenous GLP-1 to enter the brain has been debated, but the clinically used, long-acting GLP-1R agonists (liraglutide and semaglutide) have been proven to enter the brain of rodents and in these animals, can bind to central neuronal groups relevant for the weight effec…”
BackgroundSelf-citationLee, T. S., Park, E. J., Choi, M., Oh, H. S., An, Y., Kim, T. P., Kim, T. H., Shin, B. S., & Shin, S. (2023) · Journal of Chromatography B · doi:10.1016/j.jchromb.2023.123688 · Cited by 80
Amylin as a Future Obesity Treatment
Dehestani, B., Stratford, N. R., & Roux, C. W. L. (2021) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes21071 · Cited by 72
GLP-1 signaling and alcohol-mediated behaviors; preclinical and clinical evidence
Jerlhag, E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.013 · Cited by 72
Cui, Q. N., Stein, L. M., Fortin, S. M., & Hayes, M. R. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15683 · Cited by 71
“To a lesser degree, GLP-1R agonists were also present but more sparsely in distributed in nuclei throughout the brain, depending in part on what GLP-1R ligand is being analysed (Gabery et al., 2020; Secher et al., 2014).”
BackgroundLourenco, M. V., Ferreira, S. T., & Felice, F. G. D. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.03.003 · Cited by 85
Theilade, S., Christensen, M., Vilsbøll, T., & Knop, F. K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14270 · Cited by 82
The Significance of Hypothalamic Inflammation and Gliosis for the Pathogenesis of Obesity in Humans
SEWAYBRICKER, L. E., Huang, A., Chandrasekaran, S., Melhorn, S. J., & Schur, E. A. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac023 · Cited by 84
Targeting the central melanocortin system for the treatment of metabolic disorders
Sweeney, P., Gimenez, L. E., Hernández, C. C., & Cone, R. D. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00855-y · Cited by 78
Bifari, F., Manfrini, R., Dei Cas, M., Berra, C., Siano, M., Zuin, M., Paroni, R., & Folli, F. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.09.025 · Cited by 69
Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective
Michałowska, J., Miller-Kasprzak, E., & Bogdański, P. (2021) · Nutrients · doi:10.3390/nu13020351 · Cited by 68
Mansur, R. B., Zugman, A., Ahmed, J., Cha, D. S., Subramaniapillai, M., Lee, Y. L., Lovshin, J. A., Lee, J. G., Lee, J.-H., Drobinin, V., et al. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.08.433 · Cited by 73
Vagal mediation of GLP-1's effects on food intake and glycemia
Krieger, J.-P., Langhans, W., & Lee, S. J. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2015.06.001 · Cited by 67
Metadata
- Authors
- Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., Schäffer, L., Tang-Christensen, M., Verma, S., Witgen, B. M., Vrang, N., & Bjerre Knudsen, L.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Gubra (Denmark) (DK)
- Oregon National Primate Research Center (US)
- Oregon Health & Science University (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2014-09-09
- Volume
- 124
- Issue
- 10
- Pages
- 4473-4488
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4215190
- OpenAlex
- W2014156217
- Cited by
- 961
- References
- 95
- Citations by year
- 2026: 100 · 2025: 126 · 2024: 123 · 2023: 85 · 2022: 77 · 2021: 93 · 2020: 56 · 2019: 63 · 2018: 62 · 2017: 65 · 2016: 52 · 2015: 53 · 2014: 5
- FWCI
- 28.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- liraglutide, GLP-1 receptor, arcuate nucleus, weight loss, hypothalamus, proopiomelanocortin neurons, neuropeptide Y, agouti-related protein, GABAergic inhibition, circumventricular organs, GLP-1 analogues, appetite regulation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Cocaine- and Amphetamine-Regulated Transcript Protein, Animals, Arcuate Nucleus of Hypothalamus, Body Weight, Disease Models, Animal, Electrophysiology, Hypothalamus, Male, Mice, Transgenic, Nerve Tissue Proteins, Neurons, Paraventricular Hypothalamic Nucleus, Pro-Opiomelanocortin, Vagus Nerve, Weight Loss, Rats, Sprague-Dawley, Receptors, Glucagon, Mice, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.